CIP
CSTL icon

Cornerstone Investment Partners’s Castle Biosciences CSTL Stock Holding History

Cornerstone Investment Partners’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,078
Closed -$236K – 303
2025
Q4 		$236K Buy
+6,078
New +$196K 0.01% 137
2024
Q4 		– Sell
-7,085
Closed -$202K – 252
2024
Q3 		$202K Buy
+7,085
New +$180K 0.01% 177
2020
Q4 		– Sell
-4,129
Closed -$212K – 214
2020
Q3 		$212K Buy
+4,129
New +$184K 0.01% 113

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Investment Partners's CSTL Position: Q1 2026 in Review

Cornerstone Investment Partners sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 6,078 shares — an estimated $236K sold.

Cornerstone Investment Partners first reported a position in CSTL in Q3 2020 and held it in 3 quarters. The position peaked at $236K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Cornerstone Investment Partners reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Cornerstone Investment Partners sold 6,078 Castle Biosciences shares in Q1 2026, an estimated $236K.
  • Cornerstone Investment Partners first reported a position in Castle Biosciences in Q3 2020 and held it in 3 quarters.
  • Cornerstone Investment Partners's Castle Biosciences position peaked at $236K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Cornerstone Investment Partners's 13F filing for Q1 2026, filed 8 May 2026.